Pressure will rise on drugs that are less sophisticated. But the United States will still offer an environment that supports and rewards real innovation. Roche is well placed. Severin Schwan More Quotes by Severin Schwan More Quotes From Severin Schwan We have started the year with strong sales growth, driven by the newly launched products in our pharmaceuticals division, demand for our new medicines remains high. Severin Schwan business We've been watching this space for quite some time. We just feel it's now the right time to step up, the fit of Spark and Roche is really excellent. It provides us with a broad portfolio, it provides us with expertise across the value chain. Severin Schwan health-news Our best guess is, it is complementary and that actually patients will need both options — a medicine like Hemlibra, and increasingly over time, gene therapy. Severin Schwan health-news I have asked internally if we had any contact, and that is not the case. Severin Schwan politics I fundamentally believe there is no objective answer to value of life. Severin Schwan health-news I wouldn't call it resistance, I would call it practical hurdles that need to be overcome, this is a complex road. Severin Schwan company-news When the pressure is high enough in health care systems we'll more and more move toward aligning value with price. Severin Schwan company-news If it works, it is fantastic, the question is, does it really work and does it work for all cancers? Severin Schwan health-news Theoretically, it is extremely compelling, today, we typically change therapy when the cancer progresses or grows - but we know the mutations occur much, much earlier. Severin Schwan health-news Roche could have six new active pharmaceutical ingredients approved within two years. We never had this before, given the latest developments it is not at all the case any more that everything has to succeed in terms of what lies ahead with the pipeline in the near term. If even a part succeeds we are on course for further sustainable sales growth. Severin Schwan healthcare Analyst expectations now vary widely, with some saying 30 percent and others 60 percent, personally, I think we will see material price effects because I believe in the power of markets and competition. Severin Schwan company-news This whole segment is overvalued. The more time goes by, the more I am worried that this whole thing will collapse at some point and it will not be not good for the industry if there is too much volatility. Severin Schwan health-news We do lots of early-stage deals and we are doing almost nothing late-stage, with InterMune a special case. Severin Schwan health-news I think this bubble will burst at some point. Severin Schwan health-news
